Dear Shareholders and Investors,
November is Pancreatic Cancer Awareness Month. It highlights a major public health challenge that concerns us all: with the widespread use of cross-sectional imaging (CT and MRI), pancreatic cyst lesions are now detected by chance in 3% to 10% of adults. For both physicians and patients, the critical challenge is to reliably distinguish benign cysts—to avoid unnecessary major surgery—from cysts that may progress to pancreatic cancer.
In this key indication, Mauna Kea Technologies provides a concrete answer with Cellvizio®. By enabling physicians to observe the inner wall of the cyst in real time at the cellular level during an endoscopic procedure, our technology is increasingly establishing itself as a clinical standard of care, backed by landmark multicenter clinical studies, medical society guidelines, and an established reimbursement framework in the United States, our largest market.
To help you better understand what we do and visualize how this clinical application works in practice, we are pleased to share a new dedicated interactive page in our Investor Relations section:
Explore our interactive page (English Version)
To go further on this indication:
- Leading U.S. clinical research: You can visit the new website of Professor Somashekar Krishna’s Lab at The Ohio State University—one of the world’s foremost experts in pancreatic cyst endomicroscopy—presenting ten years of clinical outcomes: Visit the Krishna Lab website (Ohio State University)
- Clinician perspective (Podcast): You can also listen to Dr. Anjuli Luthra on the U.S. medical podcast Medical Design Briefs (“Earlier, More Accurate Detection of Pancreatic Cancer”): Listen on Spotify | Listen on Apple Podcasts | Episode page on Medical Design Briefs
